Molecule News and Research

RSS

New method helps scientists to determine specific protein molecular structure

The structures of many protein molecules remain unsolved even after experts apply an extensive array of approaches. An international collaboration has led to a new, high-performance method that rapidly determined the structure of protein molecules in several cases where previous methods had failed.

2 May 2011

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb Company today announced first quarter results that included strong sales and earnings growth, and several key R&D milestones—most notably U.S. regulatory approval for YERVOY. The company also confirmed guidance for the year.

30 Apr 2011

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.

29 Apr 2011

New PET imaging clinical trial to improve early esophageal, lung cancer detection

Can a simple imaging test help predict the success of cancer treatment, even before the treatment is complete? To begin to answer this question, a new National Cancer Institute-funded clinical trial is using a novel PET imaging technique that could improve the early detection of tumor growth during treatment for esophageal and lung cancer.

29 Apr 2011

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.

28 Apr 2011

Curis reports first quarter net loss of $6.8 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

New discovery in cancer and autoimmune diseases

Researchers in the Faculty of Medicine & Dentistry at the University of Alberta have made an important discovery that provides a new understanding of how our immune system "learns" not to attack our own body, and this could affect the way doctors treat patients with autoimmune diseases and cancer.

28 Apr 2011

Researchers begin approved drugs screening for clinical use against rare diseases

Researchers have begun screening the first definitive collection of thousands of approved drugs for clinical use against rare and neglected diseases. They are hunting for additional uses of the drugs hoping to find off-label therapies, for some of the 6,000 rare diseases that afflict 25 million Americans.

28 Apr 2011

Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME

Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A.

28 Apr 2011

Scientists weaken long-term memory

Could veterans of war, rape victims and other people who have seen horrific crimes someday have the traumatic memories that haunt them weakened in their brains? In a new study, UCLA life scientists report a discovery that may make the reduction of such memories a reality.

28 Apr 2011

Janssen, Beactica enter drug discovery agreement

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV.

28 Apr 2011

MIT develops new software to predict complex 3-D DNA structures

While the primary job of DNA in cells is to carry genetic information from one generation to the next, some scientists also see the highly stable and programmable molecule as an ideal building material for nanoscale structures that could be used to deliver drugs, act as biosensors, perform artificial photosynthesis and more.

28 Apr 2011

New discoveries on polycystin-1 can lead to novel kidney disease treatment

Two discoveries at UC Santa Barbara point to potential new drug therapies for patients with kidney disease. The findings are published in this week's issue of the Proceedings of the National Academy of Sciences.

27 Apr 2011

Proteostasis acquires Harvard University's two novel protein target licenses

Proteostasis Therapeutics announced today that it has acquired two exclusive licenses from Harvard University to technologies for enhancing the activity of a key cellular protein clearance mechanism, the ubiquitin-proteasome pathway.

27 Apr 2011

Biologists determine molecular structure of GluN2D receptor subunit

Structural biologists at Cold Spring Harbor Laboratory in collaboration with colleagues at Emory University have determined the molecular structure of a key portion, or subunit, of a receptor type commonly expressed in brain cells.

27 Apr 2011

Brain-derived protein in colorectal cancer

Tumor progression is usually ensured by more than one proliferative mechanism. When one of these is shut down by a specifically targeted drug, other mechanisms may emerge. While these events may lead to treatment failure, they may also become an opportunity for researchers to identify novel targets to be further explored.

27 Apr 2011

Heparan sulfate may have a key role in tumor-spurred lymphatic vessel growth

Cancer has a mighty big bag of tricks that it uses to evade the body's natural defense mechanisms and proliferate. Among those tricks is one that allows tumor cells to turn the intricate and extensive system of lymphatic vessels into something of a highway to metastasis. Yet research unveiled this week may aid in the development of therapeutics that will put the brakes on such cancer spread, and the researchers who completed the study say the findings may extend to other lymphatic disorders.

27 Apr 2011

USPTO grants Cortex patent for CX1739 AMPAKINE molecule

Cortex Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent that protects its lead AMPAKINE® molecule, CX1739.

26 Apr 2011

Pharmacyclics receives Servier's $7 million milestone payment for HDAC inhibitor

Pharmacyclics, Inc. announced today that it has received a $7 million milestone payment for its histone deacetylase inhibitor, PCI-24781 / S 78454 from Les Laboratoires Servier based on an ex-US collaboration agreement signed in April of 2009.

26 Apr 2011

HemaQuest initiates HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that clinical investigators have enrolled the first patient in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

26 Apr 2011